A new meta‑analysis compared chimeric antigen receptor T‑cell (CAR‑T) therapy with bispecific antibody treatments for relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphomas. The pooled data scored differences in response rates, durability and safety profiles across studies, highlighting tradeoffs between deep remissions with CAR‑T and off‑the‑shelf convenience of bispecifics. The analysis quantifies comparative toxicities, including cytokine release syndrome and neurotoxicity, offering clinicians evidence to weigh against manufacturing times and access limitations. Authors recommend head‑to‑head trials and standardized reporting to refine treatment sequencing.